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A number of matrix metalloproteinases (MMPs) are important medicinal targets for conditions ranging from rheumatoid arthritis
to cardiomyopathy, periodontal disease, liver cirrhosis, multiple sclerosis, and cancer invasion and metastasis, where they showed
to have a dual role, inhibiting or promoting important processes involved in the pathology. MMPs contain a zinc (II) ion in the
protein active site. Small-molecule inhibitors of these metalloproteins are designed to bind directly to the active site metal ions.
In an effort to devise new approaches to selective inhibitors, in this paper, we describe the synthesis and preliminary biological
evaluation of amino acid derivatives as new zinc binding groups (ZBGs).The incorporation of selected metal-binding functions in
more complex biphenyl sulfonamide moieties allowed the identification of one compound able to interact selectively with different
MMP enzymatic isoforms.
1. Introduction
Matrix metalloproteinases (MMPs) are 23-member zinc-
dependent endopeptidases family involved in the extracel-
lular matrix turnover [1]. Their aberrant regulation has been
implicated in tumoral process, where they showed to have
a dual role inhibiting or promoting cell growth and sur-
vival, angiogenesis and metastasis [2, 3] differentiation [4],
and inflammation and immune surveillance [5]. Moreover,
MMPs are overexpressed in a variety of tumor types, and
their overexpression is associated with tumor aggressiveness
and poor prognosis [6]. The specific alteration of the MMPs
in malignant tissues and their participation in some of
the major oncogenic mechanisms have both fuelled interest
in the design and evaluation of MMP inhibitors (MMPIs)
as anticancer agents [7, 8]. Generally, the MMPIs design
involves peptide or peptidomimetic backbones containing
a zinc-binding group (ZBG) able to interact with both the
subpockets surrounding the active site (S
1
and S󸀠
1
, S󸀠
2
, and S󸀠
3
)
and the zinc (II) ion present in the catalytic site, respectively
[9, 10]. The greater part of MMPIs research has focused
on developing the peptide or peptidomimetic containing a
hydroxamic acid as chelating group. Although this design
has produced potent inhibitors such as Batimastat [11, 12]
and Marimastat [13] (Figure 1), none of these MMPIs has
successfully completed clinical trials.
The inability of hydroxamates to produce clinically viable
compounds has been attributed to low oral availability, poor
in vivo stability, and undesirable side effects associated with
these compounds [14].This has prompted the investigation of
a limited number of nonhydroxamate-based MMPIs [15–19].
We present herein the results obtained with a small library
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Figure 1: Structures of Batimastat and Marimastat.
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Figure 2: Hypothetical interaction between ZBG and Zn2+.
of compounds synthesized and tested as potential ZBGs. The
compounds were selected on the basis of some similarities to
hydroxamates, such as the possibility to form five-member
chelates (Figure 2), but with potentially enhanced pharma-
cokinetic properties such as a better hydrolytic stability
and/or proposed increased affinity for the MMP zinc (II).
The designed ligands have a general 2-aminopropane-
1,3-disubstituted structure which might be visualized as an
amino acid derivative with the 𝛼 carbon atom connected
through two 𝛽 carbons to heteroatoms with lone pairs or
simply electron availability (R and R
1
). These functional
groups are sulfhydryl (SH), alcohol (OH), imidazole, cyano
(CN), and azide (N
3
) which are able to interact as Lewis-base
in the coordination of the catalytic zinc ion.Their symmetric
and asymmetric combination gave rise to a small ZBGs
library (Table 1).The two 𝛽 carbons rotational freedom could
allow the chelating groups R and R
1
to orient themselves as
better as possible in direction of the zinc ion.
According to the preliminary results of enzymatic inhi-
bition activities, we further synthesized, from the most
interesting ligands, a small series of sulfonamide derivatives
containing a phenoxyphenyl group. This moiety has been
widely used in the design of MMPs inhibitors as side chain
of choice able to interact with the enzymatic S󸀠
1
subsite
which plays a pivotal role in the determination of inhibition
selectivity [20, 21]. The aims of the current study were to
screen a range of nonhydroxamate structures as new ZBGs
and to evaluate the enzymatic activity of small molecules
designed to interact with the subpocket S󸀠
1
and with the zinc
(II) ion present in the catalytic site of MMPs.
Table 1: Synthesized ZBGs library.
Compounds R R
1
NH
2
R
1
R
1a OH OH
1b CN CN
1c N3 N3
1d SH OH
1e Imidazole OH
1f SH SH
1g Imidazole SH
1h SH CN
1i OH CN
1j SH N3
1k OH N3
1l Imidazole N3
NH2
OH OH
OH OH
NH2
CN CNCN CN
TFA
TFA
(Boc)2O
N3N3N3N3
NH2
OTs OTs
Tos-Cl
TEACN
NaN3
1a
2
4 1b
3 5 1c
NHBoc
NHBoc
NHBocNHBoc
Scheme 1: Synthesis of symmetric ZBGs 1a, 1b, and 1c.
2. Chemistry
The symmetric ligands were prepared starting from serinol
(1a) according to synthetic route shown in Scheme 1. After
N-Boc-protection, the alcohol groups of 2 were activated
as ditosylate derivatives in order to undergo nucleophilic
substitutionwith azide and nitrile salts.Thus, displacement of
the OTs group with tetraethylammonium cyanide (TEACN)
or sodium azide (NaN
3
) in DMF using TEA as base led
to 4 and 5, respectively, with 80%–82% yields. The final
symmetric derivatives 1b and 1c have been obtained after
deprotection of 2-amino group using a solution of 25% TFA
in dichloromethane.
The ditosylation reaction was the limiting step in this
synthetic strategy, described in the literature using pyridine
(py) as solvent [22]. In our case, the treatment of 2 with 4-
toluenesulfonyl chloride in pyridine led to ditosylate deriva-
tive 3 in only 2% yield. A preliminary study of the influence
of solvents, reaction time, and reactive/base concentration
ratio on this reaction was performed in order to (a) improve
yields and mono/ditosylate adduct ratio; (b) facilitate work-
up procedures; (c) use a less toxic solvent.
Journal of Amino Acids 3
R
O
R R
R
R R
SHR
R
R
R
6, 9, 12, 15, 17, 19
7, 10, 13, 18, 20
8, 11, 14, 16, 21 N
N
Boc
TFA
OH
OH
OH
CN CN
TFA
TFA
TFA
N3
N3
NH2
NH2
NH2
NH2
OTs
Tos-Cl TEACN
NaN3
12, 13
17, 18 1h, 1i
12, 14
1d, 1e 15, 16
1f, 1g
Trt-SH
(i) EtCOCl, NMM
(ii) NaBH4
STrt
R = STrt
R = OtBu
R =
NHBoc NHBoc NHBoc
NHBoc
NHBoc
NHBoc
6–8 9–11 12–14
19–21 1j–l
Scheme 2: Synthesis of symmetric (1f) and asymmetric (1d, 1e, 1g–1l) ZBGs.
Table 2: Study on ditosylation reactionof N-Boc-serinol (2).
Entry Solvents Reaction time TsCl : TEA Yields(%)
Mono/di
ratio
1 Py 6 h 2.4 : 3 29 10 : 1
2 Py 10 h 3 : 4 40 10 : 1
3 Py, DMAP cat 6 h 3 : 4 31 10 : 1
4 DCM, Py cat 6 h 2.4 : 3 53 5 : 1
5 DCM, Py cat 10 h 3 : 4 45 5 : 1
6 DCM 6h 3 : 4 55 1 : 1
7 dry DCM 10 h 3 : 4 68 1 : 2
8 dry DCM 10 h 2.4 : 3 85 1 : 19
As shown in Table 2, treatment of 2 with Tos-Cl and
TEA in 2.4 : 3 ratio gave the highest yields (85%) and better
selectivity (1 : 19) in the formation of ditosylate derivative 3
using dry dichloromethane as solvent (entry 8). Pyridine or
pyridine with dimethylaminopyridine as base catalyst gave
low yields with a little percentile of dialkylation product
(entries 1, 2, and 3), while DCM as solvent was more effective
without base catalyst (entries 6, 7, and 8 versus entries 4 and
5).
The symmetric and asymmetric ligands, 1f and 1d, 1e, and
1g–1l, respectively, were prepared according to the synthetic
route shown in Scheme 2.
Protected amino acids Boc-Cys(Trt)-OH (6), Boc-
Ser(OtBu)-OH (7), and Boc-His(Boc)-OH (8) were reduced
to corresponding alcohols (9–11) using sodium borohydride
as we previously described [23]. Treatment of hydroxy
derivatives 9 and 11 with 20% TFA/DCM gave directly
the corresponding final asymmetric ligands 1d and 1e.
Analogously, reaction of hydroxyl derivatives with Tos-Cl
in DCM and TEA led to tosylate intermediates 14–16 which
were submitted to nucleophilic substitution reaction with
azide and nitrile salts in the previously mentioned conditions
to give the corresponding cyano (17,18) and nitrile (19–21)
derivatives. Loss of protective groups after treatment of
intermediates 12–21 with 50% TFA/DCM solution conduced
to final compounds 1f–1l.
Finally, the N-substituted phenoxybenzensulfonamide
25a, 25d, and 25e were prepared according to synthetic
route of Scheme 3. The sulfonation of diphenylether 22
with chlorosulfonic acid (ClSO
3
H) and afterward chlori-
nation with thionyl chloride (SOCl
2
) afforded the key 4-
phenoxybenzensulfonyl chloride 24 with 95% overall yields.
The coupling of 24 with 1a, 1d, and 1e in DMF and cesium
carbonate (Cs
2
CO
3
) gave directly the corresponding final
compounds in 42%–55% yields.
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Table 3: Enzymatic inhibition of MMP-2 by 2-amino-1,3-disubsti-
tuted derivatives 1a–1l.
Compounds R R
1
IC50 (𝜇M ± SD)
O
N
H
OH
AHA
AHA 10000 ± 630
1a OH OH 280 ± 24
1b CN CN 560 ± 52
1c N3 N3 >1000
1d SH OH 674 ± 88
1e Imidazole OH 450 ± 23
1f SH SH 666 ± 90
NH
2
R
1
R
1a–1l
1g Imidazole SH 300 ± 41
1h SH CN 500 ± 49
1i OH CN 807 ± 98
1j SH N3 520 ± 57
1k OH N3 520 ± 49
1l Imidazole N3 480 ± 25
3. Enzymatic Inhibition Assays
The synthesized ZBGs, compounds 1a–1l, were tested against
the catalytic domain of MMP-2 in order to evaluate their
chelating capability with respect to acetohydroxamic acid
(AHA)which was considered a representative of the standard
hydroxamate chelator. All the examined compounds exhib-
ited a higher inhibitory activity compared to AHA (Table 3).
The enzymatic assays revealed that the most interesting
compounds are the serinol 1a and the asymmetric ligands 1e
and 1g, containing both an imidazole group and an alcohol
or a thiol group, respectively. Surprisingly, the cysteinol 1d,
despite the well-known zinc thiophilicity, showed a lower
enzymatic activity with IC
50
value of 674𝜇M.
On the basis of these data, we selected the most active lig-
ands 1a and 1e to be incorporated as ZBG in a more complex
structure. The ligands were linked, through a sulfonamide
bind, with a phenoxyphenyl group, described in the literature
for its well-validated affinity for the S󸀠
1
enzymatic subpocket
[10, 24]. A third ligand 1d, less active, was also chosen in
order to evaluate the real influence of ZBG group alone in
the enzymatic activity.
Compounds 25a, 25d, and 25ewere tested against human
recombinants MMP-1, MMP-2, MMP-8, and MMP-9 by a
Table 4: Enzymatic activity of N-substituted phenoxybenzensul-
fonamide 25a, 25d, and 25e on different MMPs.
O
S
H
N R
1
RO2
Com. R R
1
IC50 (𝜇M ± SD)
MMP-1 MMP-2 MMP-8 MMP-9
25a OH OH 1030 ± 160 71 ± 1.9 98 ± 8.0 160 ± 15
25d SH OH 819 ± 116 110 ± 10 9.1 ± 2.3 12 ± 4.0
25e Imidazole OH 480 ± 30 190 ± 8.7 330 ± 21 200 ± 15
fluorometric assay, and the obtained IC
50
values are sum-
marized in Table 4. Compound 25a exhibited an interesting
inhibitory activity on MMP-2 and MMP-8, two enzymatic
isoforms characterized by an intermediate and a deep S󸀠
1
subpocket, respectively [25–28].This compound showed also
a good selectivity overMMP-1 which has a shallow S󸀠
1
pocket.
The substitution of a hydroxyl with an imidazole group,
compound 25e, caused a loss of both potency (except on
MMP-1) and selectivity on the enzymes used in this study.The
most interesting results were obtained with compound 25d.
This compound showed a high inhibitory activity on MMP-
8 and MMP-9 with IC
50
values in the micromolar range (10-
and 13-fold more potent than 25a, resp.) and maintained a
good selectivity over both MMP-2 and MMP-1.
These preliminary results showed a different behaviour
of ZBGs when they are introduced into a more complex
structure indicating that, in this case, the modulation of
selectivity does not depend only on ZBGs [29].
4. Molecular Modeling
In order to rationalize the observed activity data, docking
calculations of the ZBGs and compounds 25a, 25d, and 25e
were performed on the MMP-2 catalytic domain. Subse-
quently, they were submitted to a refinement step, thorough
minimization of best poses. The applied protocol allowed
to correlate predicted and experimental binding energies.
It is well known that docking scores hardly correlate with
activity data, and to this aim, more accurate calculations
are required such as Free Energy Perturbation or Thermo-
dynamic Integration. Among available approaches, Linear
Interaction Energy (LIE) represents a good compromise
between accuracy and speed of calculations [30, 31]. In
this approach, the binding process is represented as the
replacement of water molecules solvating a ligand by the
protein, using an implicit water model.
LIE generates a custom scoring function calculating the
values of alpha, beta, and gamma coefficients of the following
equation:
Delta 𝐺 = alpha ∗ (𝑈 vdw 𝑏 − 𝑈 vdw 𝑓)
+ beta ∗ (𝑈 elec 𝑏 − 𝑈 elec 𝑓)
+ gamma ∗ (𝑈 cav 𝑏 − 𝑈 cav 𝑓) ,
(1)
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Figure 3: Docked poses of 1a (a) and 1e in both enantiomeric forms (b) into the MMP-2 active site. MMP-2 is represented as a grey cartoon.
Ligands and most relevant residues are depicted as sticks. H-bonds are represented as green dashed lines.
Table 5: Predicted and calculated binding energy (kcal) for all
compounds toward MMP-2.
Compound Δ𝐺 exp Δ𝐺 calc (R-model) Δ𝐺 calc (S-model)
1a −4.837 −4.628 −4.484
1b −4.428 −4.734 −4.619
1c —a —a —a
1d R
−4.319 −4.512
1d S −4.492
1e R
−4.565 −4.395
1e S −4.614
1f −4.333 −4.538 −4.592
1g R
−4.796 −4.583
1g S −4.739
1h R
−4.497 −4.421
1h S −4.303
1i R
−4.210 −4.391
1i S −4.379
1j R
−4.469 —
a —a
1j S −4.511
1k R
−4.469 −4.237
1k S −4.513
1l R
−4.524 −4.624
1l S −4.338
25a −5.655 −5.506 −5.326
25d R
−5.396 −5.349
25d S −5.279
25e R
−5.069 5.179
25e S −5.378
aNo suitable docking poses were found.
where Delta𝐺 is the calculated binding energy;𝑈xxx 𝑏 is the
van derWaals, Coulombic, and Cavity energy terms from the
bound state; 𝑈xxx 𝑓 is the van der Waals, Coulombic, and
Cavity energy terms from the free state.
LIE method applied to our ligands provided a statistically
significant correlation between calculated and experimental
data, underpinning the validity of predicted docking poses
(Table 5).
Table 6: Statistical parameters for LIE R-model and S-model.
Model 𝑅2 SD 𝐹 𝑃 𝑅2cv
R-model 0.813 0.218 13.1 0.00125 0.64
S-model 0.751 0.242 10.0 0.00232 0.511
It is worth noting that chiral compounds under study
were synthesized and tested as racemic mixture. Conse-
quently, all calculations were carried out for all enantiomers,
and quantitative models were generated for both R (R-
model) and S forms (S-model) separately. Obtained Δ𝐺
values indicate that the R-model works slightly better than the
S-model in predicting activity, as demonstrated by statistical
correlation values (Table 6); however, the S-model is able to
predict the binding energy with acceptable approximation
indicating that experimental activity can be due to the
contribution of both enantiomers.
This result is confirmed from the analysis of fragments
docking poses in fact that no relevant differences can be
observed in the binding of enantiomeric forms of chiral
compounds, in the MMP-2 active site.
Moreover, differently than expected, just ligand 1a is able
to chelate the zinc ion, providing an explanation of the
higher activity observed for this compound. Other fragments
give a monodentate binding of the catalytic zinc, and the
other electron donating group is usually involved in H-bond
interactions with surrounding residues, such as the Pro221
carbonyl oxygen (e.g., 1d), except for compounds containing
the imidazole ring (e.g., 1e), involved in a 𝜋-𝜋 stacking with
the His201 side chain, which represents one of the main
interactions formed by MMPIs in the S󸀠
1
pocket (Figure 3).
This behavior can be attributed to the strict geometrical
requirements, which must be fulfilled by chelating group
around the zinc ion in MMPs active site.
The binding of sulfonamide derivatives 25a, 25d, and
25e was studied as well through docking calculation and
subsequent refinement as previously described on MMP-1,
-8, and -9 (Table 7). No statistical correlations are provided in
these cases because of the few available data. Docking results
show all ligands occupying the S󸀠
1
site, except for MMP-1.
This isoform, in fact, is known for having a short S󸀠
1
pocket,
unable to accommodate the large biphenylether portion of
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Table 7: Predicted and calculated binding energy (kcal) for sulfonamide ligands toward MMP-1, -8, and -9.
Compound MMP-1 MMP-8 MMP-9
Δ𝐺 exp Δ𝐺 calc Δ𝐺 exp Δ𝐺 calc Δ𝐺 exp Δ𝐺 calc
25a −4.074 −4.098 −5.460 −5.532 −5.178 −5.168
25d R
−4.224 −4.247 −6.870 −6.504 −6.705 −6.840
25d S −4.176 −6.870 −6.528
25e R
−4.524 −4.527 −4.740 −4.365 −5.042 −4.970
25e S −4.522 −5.408 −5.165
Ala165
Glu202
Pro221
Leu164
(a)
Ala161
Glu198
Leu160
(b)
Figure 4: Docked poses of 25a into the MMP-2 active site (a) and 25d into MMP-8 active site (b). MMP-2 and MMP-8 are represented,
respectively, as a grey and dark grey cartoons. Ligands and most relevant residues are depicted as sticks. H-bonds are represented as green
dashed lines.
these ligands. The imidazole ring of compounds 25e, the
more active towards MMP-1, occupy the hydrophobic pocket
of this protein.
Binding mode of sulfonamide derivatives to the other
MMPs is well conserved, regardless of chirality: MMP-2, -8,
and -9 have a deep S󸀠
1
site able to locate the hydrophobic
biphenyl ether, whose proximal aromatic ring interacts with
the imidazole ring of His201, and the distal ring provides
hydrophobic interactions in binding pocket.The sulfonamide
moiety provides two H-bonds between a sulfone oxygen
and Ala165 and Leu164 NH (MMP-2 numbering) and the
sulfonamide NH and the Pro221 CO or alternatively Ala165
CO (Figure 4). Main differences are observed for the binding
of the ZBG; in MMP-2, the ZBG of 25amaintains the ability
to chelate the zinc ion.
This chelation, not observed in MMP-8 and -9, can
explain the higher activity observed for this ligand inMMP-2.
MMP-8 and -9 zinc ions coordinate all ligands in a
monodentate fashion with a similar geometry, similarly to
what observed for the ZBG in MMP-2. Therefore, as no
chelation is provided by the ZBG inMMP-8 andMMP-9, the
zinc thiophilicity seems to play a relevant role in determining
activity toward these isoforms.
5. Conclusion
Herein,we described the design, synthesis, inhibitory activity,
and molecular modeling studies of new non-hydroxamate-
based MMPIs. The adopted synthetic strategy enabled the
setting-up of a small ZBGs library through a simple and
easily accessible pool of reactions. The biological screening
of this library led to the identification of two ZBGs that were
incorporated in a more complex structure able to interact
with the S󸀠
1
enzymatic site.The biological data for compounds
25a and 25e confirmed the inhibition trend of the respective
ZBGs against MMP-2. Compound 25d, containing a less
potent chelating group (1d versus 1a and 1e), was equipotent
to 25a against MMP-2 and more potent than 25a against
MMP-8 andMMP-9 (10- and 13-fold, resp.). Molecular mod-
eling studies provided a rationalization of the experimental
data, suggesting a putative binding mode of studied ligands
in MMPs active site. These preliminary results indicate
the importance of testing and selecting firstly compounds
containing the minimums structural requirements necessary
for a specific biological activity. Furthermore, taking in
consideration the complex role of MMPs in the cellular and
tumoral homeostasis, the development of selective inhibitors
is desirable in order to shed further light on the protein
function, signalling pathways, and role in disease of different
MMPs [32–34]. Thus, compound 25d identified in this
preliminary study as MMP-8 and MMP-9 inhibitors could
be submitted to a rational process of hit optimization with
the aim to improve its potency and selectivity of action.
The introduction of these new fragments into different
peptide structures with the aim to synthesize selective MMPs
inhibitors and to explore their structure-activity relationships
is currently under study in our laboratory.
6. Experimental
6.1. MMP Inhibition Assays. Pro-MMP-1, pro-MMP-2, pro-
MMP-8, and pro-MMP-9 were purchased from Calbiochem.
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Proenzymes were activated immediately prior to use with 𝑝-
aminophenylmercuric acetate (APMA 2mM for 1 h at 37∘C
for MMP-2 and MMP-8, APMA 2mM for 2 h at 37∘C for
MMP-1, and APMA 1mM for 1 h at 37∘C for MMP-9). For
assay measurements, the inhibitor stock solutions (10mM in
DMSO) were further diluted, at seven different concentra-
tions (0.01 nM–200𝜇M) for each MMP in the fluorometric
assay buffer (FAB: Tris 50mM, pH = 7.5, NaCl 150mM,
CaCl
2
10mM, Brij 35 0.05%, and DMSO 1%). Activated
enzyme (final concentration 0.56 nM for MMP-2, 1.3 nM for
MMP-9, 1.5 nM for MMP-8, and 2.0 nM for MMP-1) and
inhibitor solutions were incubated in the assay buffer for
4 h at 25∘C. After the addition of 20𝜇M solution of the
fluorogenic substrate Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-
Ala-Arg-NH
2
(Bachem) for all the enzymes in DMSO (final
concentration 2𝜇M), the hydrolysis was monitored every 15 s
for 15min recording the increase in fluorescence (𝜆ex =
325 nm; 𝜆em = 395 nm) using a Molecular Devices Spec-
traMax Gemini XS plate reader. The assays were performed
in triplicate in a total volume of 200𝜇L per well in 96-
well microtiter plates (Corning, black, NBS). The MMP
inhibition activity was expressed in relative fluorescent units
(RFUs). Percent of inhibition was calculated from control
reactions without the inhibitor. IC
50
was determined using
the formula: 𝑉
𝑖
/𝑉
𝑜
= 1/(1 + [I]/IC
50
), where 𝑉
𝑖
is the initial
velocity of substrate cleavage in the presence of the inhibitor
at concentration [I], and 𝑉
𝑜
is the initial velocity in the
absence of the inhibitor. Results were analyzed using SoftMax
Pro software and Origin software.
6.2. General. Reagents, starting materials, and solvents were
purchased from commercial suppliers and used as received.
Analytical TLC was performed on plates coated with a
0.25mm layer of silica gel 60 F254 Merck and preparative
TLC on 20 cm × 20 cm glass plates coated with a 0.5mm
layer of silica gel PF254Merck. Silica gel 60 (300–400 mesh,
Merck) was used for flash chromatography. Melting points
were determined by a Kofler apparatus and are uncorrected.
1H NMR and 13C NMR spectra were recorded with a
Varian-400 spectrometer, operating at 400 and 100MHz,
respectively. Chemical shifts are reported in 𝛿 values (ppm)
relative to internal Me
4
Si, and 𝐽 values are reported in hertz
(Hz). ESIMS experiments were performed on an Applied
Biosystems API 2000 triple-quadrupole spectrometer.
6.2.1. 2-(tert-Butyloxycarbonyl)-1,3-dihydroxypropane (2). To
a 25mL round-bottom flask, 2-aminopropane-1,3-diol 1a
(11mmol) (Sigma-Aldrich, 98%) was added and dissolved in
a 1 : 1 mixture water/1,4-dioxan (10mL). After few minutes,
di-tert-butyl dicarbonate (1.2 eq) and KOH until pH 8 were
added. The reaction was stirred for 48 h, washed with H
3
O+,
dried with Na
2
SO
4
, and evaporated under reduced pressure
(yield: 98%); 1H-NMR (400MHz, CDCl
3
) 𝛿 1.34 (s, 9H, Boc);
𝛿 3.59–3.63 (m, 1H, H-2); 𝛿 3.72–3.87 (m, 4H, H-1 and H-3);
𝛿 5.15 (bs, 1H, NHBoc)).
6.2.2. 2-(tert-Butoxycarbonylamino)propane-1,3-diyl bis(4-
Methylbenzenesulfonate) (3). To a 25mL round-bottom
flask, 2 (10mmol) was added and dissolved in dry DCM
(10mL). After reached 0∘C, paratoluensulfonyl chloride (2.4
eq) and TEA (3 eq) were added. The reaction was stirred for
10 h, washed with water, dried with Na
2
SO
4
, and evaporated
under reduced pressure. The crude was then purified by
chromatographic column using 𝑛-hexane/AcOEt 2 : 1 as
eluent (yield: 85%); 1H-NMR (400MHz, CDCl
3
) 𝛿 1.34 (s,
9H, Boc); 4.00–4.06(m, 5H, H-1, H-2, and H-3); 4.89 (bs,
NHBoc); 7.31 (d, 𝐽 = 8Hz, 4H, aryl); 7.71 (d, 4H, aryl).
7. General Procedure for the Synthesis of
Symmetric Ligands
3-Aminopentanedinitrile (1b) and
1,3-Diazidopropan-2-amine (1c)
To a 25mL round-bottom flask, 3 (5mmol) was added and
dissolved in DMF (10mL). TEA (3 eq) and TEACN (2.4 eq)
or NaN
3
(2.4 eq) were then added, and the reaction was
stirred for 10 h at room temperature. The reaction mixtures
were washed with water, dried with Na
2
SO
4
, and evaporated
under reduced pressure. The crudes 4 and 5 were purified by
chromatographic column using 𝑛-hexane/AcOEt: 3/1 as elu-
ent. Data for tert-butyl 1,3-dicyanopropan-2-ylcarbamate (4),
Data for tert-butyl 1,3-dicyanopropan-2-ylcarbamate (4) 1H-
NMR(400MHz,CDCl3): 𝛿 1.41 (s, 9H); 2.73–2.82 (m, 4H,H-2
andH-4); 3.47–3.50 (m, 1H, H-3); 5.06 (bs, 1H, NHBoc). Data
for tert-butyl 1,3-diazidopropan-2-ylcarbamate (5) 1H-NMR
(400MHz, CDCl3): 𝛿 1.49 (s, 9H, Boc); 3.40–3.52 (m, 4H, H-
1 and H-3); 3.86–3.90 (m,1H, H-2); 4.77 (bs, 1H,NHBoc). A
solution of derivatives 4 or 5 (1mmol) in CH
2
Cl
2
(10mL)
was treated with trifluoroacetic acid (10mL) and stirred at
room temperature. The reaction was stirred for 2 h at room
temperature and evaporated under reduced pressure to yield
the corresponding final products as TFA salt.
7.1. 3-Aminopentanedinitrile Trifluoroacetate (1b). Yield:
36%. 1H-NMR (400MHz, CD
3
OD) 𝛿 3.00–3.03 (m, 4H,
H-2 and H-4); 3.07 (t, 1H, 𝐽 = 6.0Hz). 13C-NMR (100MHz,
CD
3
OD) 𝛿 20.7 (C-3, C-4), 39.5 (C-3), 114.9 (CN). ESI-MS
calc for C
15
H
17
NO
5
S 323.08, found 323.16.
7.2. 1,3-Diazidopropan-2-amine Trifluoroacetate (1c). Yield:
33%. 1H-NMR (400MHz, CD
3
OD) 𝛿 3.46–3.48 (m, 1H,
H-2); 3.63–3.77 (m, 4H, H-1, H-3). 13C-NMR (100MHz,
CD
3
OD) 𝛿 52.0 (C-2), 59.0 (C-1 and C-3). ESI-MS calc for
C
15
H
17
NO
5
S 323.08, found 323.16.
8. General Procedure for Synthesis of Amino
Alcohols Derived from Amino Acids (9–11)
Ethyl chloroformate (1.2 eq) and N-methylmorfoline (1.2 eq)
at 0∘C were added to a solution of Boc-Cys(Trt)-OH (6)
or Boc-Ser(OtBu)-OH (7) or flask Boc-His(Boc)-OH (8)
(1mmol) in THF (4mL). After 1 h, the reaction was filtered
off, and NaBH
4
(3 eq) dissolved in 2mL of water was added.
The reaction was then stirred at room temperature for 3 h,
washed with H
3
O+, dried with Na
2
SO
4
, and evaporated
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under reduced pressure. Chromatography purification of the
corresponding residues using 𝑛-hexane/AcOEt: 2/1 yielded,
in each case, the amino alcohol derivatives.
8.1. tert-Butyl 1-Hydroxy-3-(tritylthio)propan-2-ylcarbamate
(9). Yield: 73%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.38 (s, 9H,
Boc); 2.40–2.42 (m, 2H, H-3); 3.46–3.51 (m, 3H, H-1, H-2);
4.77 (bs, 1H, NHBoc); 7.20–7.44 (m, 15H, aryl).
8.2. tert-Butyl 1-(tert-Butoxy)-3-hydroxypropan-2-ylcarbam-
ate (10). Yield: 69%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.08 (s,
9H); 1.41 (s, 9H); 3.12 (m, 1H, H-3); 3.41–3.49 (m, 2H, H-1,
H-3); 3.62 (m, 2H, H-1, H-2); 5.12 (s, NHBoc).
8.3. tert-Butyl 1-Hydroxy-3-(1H-imidazol-4-yl)propan-2-ylc-
arbamate (11). Yield: 80%. 1H-NMR (400MHz, CDCl
3
) 𝛿
1.39 (s, 9H); 1.45 (s, 9H); 2.61–2.72 (m, 2H, H-1); 3.12–3.21 (m,
2H, H-3); 3.62 (m, 1H, H-2); 4.98 (bs, NHBoc); 7.00 (s, 1H,
imidazole); 8.21(s, 1H, imidazole).
9. General Procedure for Removal of the
Boc Protecting Group: Synthesis of Final
Ligands 1d and 1e
The compounds 9 or 11 were dissolved in a 1 : 1 mixture
DCM/TFA (10mL), adding triethylsilane (0.1 eq) as scav-
enger. The reaction was stirred for 2 h at room temperature
and evaporated under reduced pressure to yield the title
derivatives as TFA salt.
9.1. 2-Amino-3-mercaptopropan-1-ol Trifluoroacetate (1d).
Amorphous solid (46%). 1H-NMR (400MHz, D
2
O) 𝛿 2.45–
2.49 (m, 2H, H-3); 3.15–3.19 (m, 1H, H-2); 3.67–3.71 (m, 2H,
H-1). 13C NMR (100MHz, D
2
O) 𝛿 30.2 (C-3) 57.2 (C-2), 63.1
(C-1). ESI-MS calc for C
5
H
10
F
3
NO
3
S 221.20, found 221.29.
9.2. 2-Amino-3-(1H-imidazol-4-yl)propan-1-ol Ditrifluoroac-
etate (1e). White solid (39%), m.p. 218–220∘C. 1H NMR
(400MHz, CD
3
OD) 𝛿 2.90–2.93 (m, 2H, H-3); 3.08–3.12 (m,
1H, H-1); 3.66–3.71 (m, 2H, H-1); 7.01 (s, 1H, imidazole); 7.89
(s, 1H, imidazole). 13H-NMR (100MHz, CD
3
OD) 𝛿 29.4 (C-
3), 58.2 (C-2), 64.1 (C-1) 118.2, 130.1, 134.7 (imidazole). ESI-
MS calc for C
10
H
13
F
6
N
3
O
5
369.22, found 369.16.
10. General Procedure for Synthesis of
Tosilated Derivatives 12–14
To a 25mL round-bottom flask, 9, 10, or 11 (1.1mmol) was
added and dissolved in dry DCM (10mL). After reached 0∘C,
paratoluensulfonyl chloride (1.2 eq) and TEA (1.5 eq) were
added. The reaction is stirred for 10 h, washed with water,
dried with Na
2
SO
4
, and evaporated under reduced pressure.
The crudes were then purified by chromatographic column
using 𝑛-hexane/AcOEt: 3/1 as elution system.
10.1. 2-(tert-Butoxycarbonylamino)-3-(tritylthio)propyl 4-Met-
hylbenzenesulfonate (12). Yield: 73%. 1H-NMR (400MHz,
CDCl
3
) 𝛿 1.43 (s, 9H); 2.30 (s, 3H, CH
3
); 2.33–2.42 (m, 2H,H-
3); 3.55–3.58 (m, 1H, H-1); 3.89–3.93 (m, 3H, H-1, H-2), 4.48
(bs, NHBoc); 7.21–7.37 (m, 17 H, aryl); 7.72 (d, 𝐽 = 8.0Hz, 2H,
aryl).
10.2. 3-tert-Butoxy-2-(tert-butoxycarbonylamino)propyl
4-Methylbenzenesulfonate (13). Yield: 77%. 1H-NMR
(400MHz, CDCl
3
) 𝛿 1.08 (s, 9H); 𝛿 1.43 (s, 9H); 2.31 (s, 3H,
CH
3
); 3.14–3.23 (m, 2H, H-1, H-3); 3.87–3.91 (m, 2H, H-1,
H-3); 4.02–4.08 (m, 1H, H-2); 4.92 (bs, NHBoc); 7.16 (d,
𝐽 = 8.1Hz, 2H, aryl); 7.89 (d, 2H, aryl).
10.3. tert-Butyl 4-(2-(tert-Butoxycarbonylamino)-3-(tosyloxy)
propyl)-1H-imidazole-1-carboxylate (14). Yield: 73%. 1H-
NMR (400MHz, CDCl
3
) 𝛿 1.38 (s, 9H); 1.41 (s, 9H); 2.31 (s,
3H, CH
3
); 2.59–2.65 (m, 2H, H-1); 3.53–3.56 (m, 1H, H-3);
3.74–3.82 (m, 1H, H-3); 4.00–4.07 (m, 1H, H-2); 𝛿 5.01 (bs,
NHBoc); 7.01 (s, 1H, imidazole); 7.19 (d, 𝐽 = 8.0Hz, 2H, aryl);
7.80 (d, 2H, aryl); 7.89 (s, 1H, imidazole).
11. General Procedure for the Synthesis of
Thio Derivatives 15 and 16
To a 25mL round-bottom flask, 12 or 14 (1.1mmol) was
added, and dissolved in DMF (10mL). TEA (1.5 eq) and Trt-
SH (1.2 eq) were then added and the reaction was stirred
for 10 h at room temperature. The reaction mixture was
then washed with water, dried with Na
2
SO
4
, and evaporated
under reduced pressure. The crudes were then purified by
chromatographic column using TLC: 𝑛-hexane/AcOEt: 4/1 as
eluent system.
11.1. tert-Butyl 1,3-bis(Tritylthio)propan-2-ylcarbamate (15).
Yield: 81%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.39 (s, 9H); 2.38–
2.41 (m, 4H, H-1, H-3); 4.01–4.05 (m, 1H, H-2); 4.48 (bs,
NHBoc); 7.08–7.23 (m, 30H, aryl).
11.2. tert-Butyl 4-(2-(tert-Butoxycarbonylamino)-3-(tritylthio)
propyl)-1H-imidazole-1-carboxylate (16). Yield: 79%. 1H-
NMR (400MHz, CDCl
3
) 𝛿 1.42 (s, 9H); 2.51–2.64 (m,
4H, H-1, H-3); 4.20–4.26 (m, 1H, H-2); 4.48 (bs, NHBoc);
7.08–7.23 (m, 16H, aryl); 7.91 (s, 1H, imidazole).
12. Synthesis of Final Ligands 1f and 1g
The compounds 15 or 16 were dissolved in a 1 : 1 mixture
DCM/TFA (10mL), adding triethylsilane (0.1 eq) as scav-
enger. The reaction was stirred for 2 h at room temperature
and evaporated under reduced pressure to yield the title
derivatives as TFA salt.
12.1. 2-Aminopropane-1,3-dithiol Trifluoroacetate (1f). Amor-
phous solid (59%). 1H NMR (400MHz, D
2
O) 𝛿 2.64 (dd,
2H, 𝐽 = 6.8 and 11.2Hz, H-1, H-3); 2.74 (dd, 𝐽 = 5.2 and
6.9Hz, 2H, H-1, H-3). 13C NMR (100MHz, D
2
O) 𝛿 30.1 (C-
1, C-3), 55.0 (C-2). ESI-MS calc for C
5
H
10
F
3
NO
2
S
2
: 237.01;
found 237.11.
12.2. 2-Amino-3-(1H-imidazol-2-yl)propane-1-thiol Ditrifluo-
roacetate (1g). White solid (61%), m.p. 196–198∘C. 1H NMR
(400MHz, CD
3
OD) 𝛿 2.79 (dd, 1H, 𝐽 = 5.7 and 10.1 Hz, H-1);
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2.90 (dd, 1H, H-1); 3.18–3.25 (m, 2H, H-3); 3.61–3.70 (m, 1H.
H-2). 13H-NMR (100MHz, CD
3
OD) 𝛿 25.8 (C-1); 26.4 (C-3),
52.3 (C-2), 118.2 (imidazole), 134.7 (imidazole). ESI-MS calc
for C
8
H
12
F
3
N
3
O
2
S: 271.06; found 271.10.
13. General Procedure for the Synthesis of
Cyano Derivatives 17 and 18
To a 25mL round-bottom flask, 12 or 13 (1.1mmol) was
added and dissolved in DMF (10mL). TEA (1.5 eq) and
TEACN (1.2 eq) were added, and the reaction was stirred for
10 h at room temperature. The reaction mixtures were then
washedwith water, dried withNa
2
SO
4
, and evaporated under
reduced pressure. The crudes were purified by chromato-
graphic column using 𝑛-hexane/AcOEt: 3/1
13.1. tert-Butyl 1-Cyano-3-(tritylthio)propan-2-ylcarbamate
(17). Yield: 84%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.42 (s,
9H,); 2.29–2.33 (m, 2H, H-3); 2.71–2.86 8m, 2H, H-1);
3.86–3.91 (m, 1H, C-2); 4.97 (bs, NHBoc); 𝛿 7.08–7.45 (m,
15H, aryl).
13.2. tert-Butyl 1-tert-Butoxy-3-cyanopropan-2-ylcarbamate
(18). Yield: 81%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.12 (s, 9H);
1.41 (s, 9H); 2.69 (m, 2H, H-3); 3.23–3.41 (m, 2H, H-1); 3.90–
3.94 (m, 1H, H-2); 4.99 (bs, NHBoc).
14. Synthesis of Final Ligands 1h and 1i
The intermediates 17 and 18 were dissolved in a 1 : 1 mixture
DCM/TFA (10mL), adding triethylsilane (0.1 eq) as scav-
enger. The reaction was stirred for 2 h at room temperature
and evaporated under reduced pressure to afford the title
compounds as TFA salt.
14.1. 3-Amino-4-mercaptobutanenitrile Trifluoroacetate (1h).
Amorphous solid (65%). 1H NMR (400MHz, CD
3
OD) 𝛿
3.09–3.20 (m, 4H, H-2, H-4); 3.87–3.90 (m, 1H, H-3). 13C
NMR (100MHz, CD
3
OD) 𝛿 20.3 (C-2), 38.3 (C-4), 46.1 (C-
3), 115.4 (C-1). ESI-MS calc for C
6
H
9
F
3
N
2
O
2
S 230.01, found
230.12.
14.2. 3-Amino-4-hydroxybutanenitrile Trifluoroacetate (1i).
White solid (63%), m.p. 131–133∘C. 1H-NMR (400MHz,
CD
3
OD) 𝛿 2.41–2.53 (m, 2H, H-2); 3.76–3.89 (m, 3H, H-3,
H-4). 13C NMR (100MHz, CD
3
OD) 𝛿 21.1 (C-2), 50.0 (C-3),
61.3 (C-4), 114.7 (C-1) ESI-MS calc for C
6
H
9
F
3
N
2
O
3
214.06,
found 214.16.
15. General Procedure for the Synthesis of
Azido Derivatives 19–21
To a 25mL round-bottom flask, 12, 13, or 14 (1.1mmol) were
added and dissolved in DMF (10mL). TEA (3 eq) and NaN
3
(2.4 eq) were added, and the reactions were stirred for 10 h at
room temperature. The reaction mixtures were washed with
water, dried with Na
2
SO
4
, and evaporated under reduced
pressure. The crudes were then purified by chromatographic
column using 𝑛-hexane/AcOEt: 3/1 as eluent system.
15.1. tert-Butyl 1-Azido-3-(tritylthio)propan-2-ylcarbamate
(19). Yield: 75%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.49 (s, 9H);
2.54–2.62 (m, 2H, H-3); 3.29–3.35 (m, 2H, H-1); 3.88–3.90
(m, 1H, H-2); 4.82 (bs, NHBoc).
15.2. tert-Butyl 1-Azido-3-tert-butoxypropan-2-ylcarbamate
(20). Yield: 72%. 1H-NMR (400MHz, CDCl
3
) 𝛿 1.18 (s, 9H);
1.43 (s, 9H); 3.01–3.23 (m, 2H, H-1); 3.81–3.90 (m, 3H, H-2,
H-3); 4.91 (bs, NHBoc).
15.3. tert-Butyl 4-{3-Azido-2-[(tert-butoxycarbonyl)amino]
propyl}-1H-imidazole-1-carboxylate (21). Yield: 70%. 1H-
NMR (400MHz, CDCl
3
) 𝛿 1.39 (s, 9H); 1.59 (s, 9H); 3.21–3.33
(m, 4H, H-1, H-3); 3.98–4.03 (m, 1H, C-2); 4.50 (bs, NHBoc).
16. Synthesis of Final Derivatives 1j–1l
The intermediates 19, 20, and 21 were dissolved in a 1 : 1
mixture DCM/TFA (10mL), adding triethylsilane (0.1 eq)
as scavenger. The reaction was stirred for 2 h at room
temperature and evaporated under reduced pressure to afford
the title compounds as TFA salt.
16.1. 2-Amino-3-azidopropane-1-thiol Trifluoroacetate (1j).
Amorphous solid (38%). 1H-NMR (400MHz, D
2
O) 𝛿 2.76–
2.82 (m, 2H, H-3); 3.58–3.62 (m, 2H, H-2, H-1); 3.78–3.81 (m,
1H, H-1). 13C NMR (100MHz, D
2
O) 𝛿 30.6 (C-1), 51.8 (C-
2), 58.9 (C-3). ESI-MS calc for C
5
H
9
F
3
N
4
O
2
S 264.04, found
264.12
16.2. 2-Amino-3-azidopropane-1-ol Trifluoroacetate (1k).
Amorphous solid (35%). 1H-NMR (400MHz, D
2
O) 𝛿
3.30–3.33 (m, 1H, H-2); 3.40–3.46 (m, 2H, H-3); 3.53–3.64
(m, 2H, H-1). 13C NMR (100MHz, D
2
O) 𝛿 50.2 (C-3), 52.0
(C-2), 59.1 (C-1). ESI-MS calc for C
5
H
9
F
3
N
4
O
3
230.15, found
230.27.
16.3. 1-Azido-3-(1H-imidazol-4-yl)propan-2-amine Ditrifluo-
roacetate (1l). Amorphous solid (41%). 1H-NMR (400MHz,
CD
3
OD) 𝛿 3.12–3.15 (m, 2H, H-1); 3.62–3.66 (m, 1H,
H-2); 3.62–3.66 (m, 1H, H-2); 3.70–3.83 (m, 2H, H-3);
7.48 (s, 1H, imidazole); 8.86 (s, 1H, imidazole). 13C NMR
(100MHz, CD
3
OD) 𝛿 25.3 (C-3), 49.7 (C-2), 51.2 (C-1), 118.1,
128.1,134.7(C-imidazole). ESI-MS calc for C
10
H
12
F
6
N
6
O
4
394.23, found 394.31.
16.4. 4-Phenoxybenzene-1-sulfonyl Chloride (24). In a 25mL
round-bottom flask, 22 (11.75mmol) was dissolved in dry
DCM (10mL), and chlorosulphonic acid (11.75mmol.) was
added at 0∘C. The reaction was stirred for 2 h, evaporated
under vacuum, and used for next step without further
purification. The reaction mixture was indeed dissolved in
thionyl chloride at 0∘C and refluxed for 5 h to yield after
evaporation product 24with 95% yield. 1H-NMR (400MHz,
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CDCl
3
) 𝛿 7.01–7.14 8m, 5H, aryl); 7.41 (d, 𝐽 = 8.6Hz, 2H, aryl);
7.82 (d, 2H, aryl).
16.5. N-(1,3-Dihydroxypropan-2-yl)-4-phenoxybenzenesulfon-
amide (25a). To a 25mL round-bottom flask, 1a (3mmol)
was added and dissolved in acetone (10mL). NaHCO
3
(1.5 eq.) and 24 (1.2 eq.) were added, and the reaction was
stirred for 24 h at room temperature. The reaction mix-
ture was then washed with water, dried with Na
2
SO
4
, and
evaporated under reduced pressure. The crude was purified
by chromatographic column using AcOEt/acetone 9/1 as
eluent system. Amorphous solid (55%). 1H-NMR (400MHz,
CD
3
OD) 𝛿 3.19–3.21 (m, 1H, H-2); 3.48–3.54 (m, 4H, H-1,
H-3); 7.04–7.09 (m, 5H, aryl); 7.40–7.43 (m, 2H, aryl); 7.84–
7.89 (m, 2H, aryl). 13C NMR (100MHz, CD
3
OD) 𝛿 56.7 (C-
2), 60.9 (C-1, C-3), 117.4, 117.7, 120.0, 121.4, 129.2, 130.1, 132.3,
151.1, 159.2(aryl). ESI-MS calc for C
15
H
17
NO
5
S 323.08; found
323.16.
16.6. N-(1-Hydroxy-3-mercaptopropan-2-yl)-4-phenoxyben-
zenesulfonamide (25d). To a 25mL round-bottom flask, 2-
amino-3-(tritylthio)propan-1-ol (3mmol) were added and
dissolved in DMF (10mL). Cs
2
CO
3
(1.5 eq.) and 24 (1.2 eq.)
were then added, and the reaction was stirred for 24 h at
room temperature. The reaction mixtures were washed with
water, dried with Na
2
SO
4
, and evaporated under reduced
pressure. The compound N-(1-hydroxy-3-(tritylthio)propan-
2-yl)-4-phenoxybenzenesulfonamide was purified by chro-
matographic column using 𝑛-hexane/AcOEt: 2/1. Yield: 42%.
1H-NMR (400MHz, CDCl
3
) 𝛿 2.34 (d, 𝐽 = 8.0Hz, 2H,
H-3); 3.18–3.23 (m, 1H, H-2); 3.42–3.49 (m, 2H, H-1); 7.14–
7.70 (m, 24H, aryl); 7.74 (d, 2H, aryl). This intermediate was
then dissolved in a 1 : 1 mixture DCM/TFA (10mL), adding
triethylsilane (0.1 eq) as scavenger. The reaction was stirred
for 2 h at room temperature and evaporated under reduced
pressure to afford the title compound as an amorphous solid.
Yield: 92%. 1H-NMR (400MHz, CDCl
3
) 𝛿 2.65–2.70 (m, 2H,
H-3); 3.35–3.40 (m, 1H, H-2); 3.64–3.79 (m, 2H, H-1); 7.03–
7.09 (m, 5H, aryl); 7.37 (d, 𝐽 = 6.8Hz, 2H, aryl); 7.84 (d, 2H,
aryl). 13C NMR (100MHz, CDCl
3
) 𝛿 26.6 (C-3), 51.1 (C-1),
62.9 (C-3), 118.0, 121.0, 129.6, 130.5, 138.2, 152.0, 160.1(aryl).
ESI-MS calc for C
15
H
17
NO
4
S
2
339.06; found 339.12.
16.7. N-(1-Hydroxy-3-(1H-imidazol-4-yl)propan-2-yl)-4-phe-
noxybenzenesulfonamide Hydrochloride (25e). To a 25mL
round-bottom flask, 1e (3mmol) was added and dissolved
in DMF (10mL). Cs
2
CO
3
(1.5 eq.) and 24 (1.2 eq.) were
then added, and the reaction was stirred for 24 h at room
temperature. The reaction mixture was then washed with
water, dried with Na
2
SO
4
, and evaporated under reduced
pressure. The product was precipitated from the crude with
dry HCl/eter solution and the filtered washed with Et
2
O.
White solid (51%) 241–243∘C. 1H-NMR (400MHz, CD
3
OD)
𝛿 2.78–2.85 (m, 2H, H-3); 3.47–3.52 (m, 2H, H-1, H-2); 3.68–
3.71 (m, 1H, H-1); 𝛿 7.02–7.10 (m, 5H, aryl); 7.39 (d, 𝐽 =
8.8Hz, 2H, aryl); 7.48 (s, 1H, imidazole); 7.80 (d, 2H, aryl);
8.85 (s, 1H, imidazole). 13C NMR (100MHz, CD
3
OD) 𝛿 28.4
(C-3), 52.6 (C-1), 63.2 (C-3), 114.0, 117.8, 118.2, 120.10, 121.4,
129.2, 130.1, 133.2, 139.8, 151.1, 159.2 (aryl). ESI-MS calc for
C
18
H
20
ClN
3
O
4
S 2409.89, found 409.91.
17. Molecular Modeling
All calculations were performed on a DELL T5500 worksta-
tion, equipped with two Intel Xeon E5630 2.53GHz proces-
sors.
All compounds were manually built in Maestro version
9.3.5, [35] exploiting the Built facility and minimized to a
derivative convergence of 0.001 kJA˚−1mol−1, using the Trun-
cated Newton Conjugate Gradient (TNCG) minimization
algorithm, the OPLS2005 force field, and the GB/SA water
solvation model implemented in MacroModel version 9.9
[23].
Conformational searches, applying the mixed torsional/
low-mode sampling and the automatic setup protocol, were
carried out on all minimized ligand structures to obtain the
globalminimumgeometry of eachmolecule, to be used as the
starting conformation for docking calculations with Glide,
version 5.8 [24, 36, 37].
Three-dimensional coordinates of MMP-1, -2, -8, and
-9 were downloaded from the Brookhaven Protein Data
Bank [38] (PBD ID: 1HFC, 1QIB, 1I76, and 1GKC, resp.).
Each 3D structure was submitted to the Protein Preparation
routine in Maestro that allows fixing of receptor structures,
eliminating water molecules and possible ligands, fixing
bond orders, adding hydrogen atoms, and ionizing charged
residues. Hydrogen bond network is optimized, and for each
structure, a brief relaxation was performed using an all-
atom constrained minimization carried out with the Impact
Refinement module version 5.8 and the OPLS-2005 force
field to reduce steric clashes that may exist in the original
PDB structures. The minimization was terminated when the
energy converged or the root mean square deviation (RMSD)
reached a maximum cut-off of 0.30 A˚.
Glide energy grid was generated using the crystallo-
graphic ligand of 1I76 as the centre of the grid, after super-
imposing all MMPs structures under study. The size of the
box was determined automatically on the basis of the ligand
dimensions. The global minimum geometry of ligands was
submitted to docking calculations in the previously prepared
proteins. The van der Waals radii for nonpolar ligand atoms
were scaled by a factor of 0.8, thereby decreasing penalties
for close contacts. Receptor atoms were not scaled. A first
docking run was carried out applying the Standard Precision
settings of Glide. Ten poses were saved and resubmitted to
docking with the Extra Precision (XP) settings; [39] one pose
was saved in this second run. The best ranking pose for each
ligand in each protein was submitted to Liaison [29] to derive
the scoring function applying the LIE method. Ligands and
receptors structures were minimized in free and bound states
through 1000 TNCG steps, allowing receptor residues 15 A far
from the ligand to be freely relaxed. Implicit GB/SA solvent
model was applied for solvation energy calculation.
The calculated 𝑈vdW, 𝑈ele, and 𝑈cav parameters were
correlated to experimental activity data using Strike [30] and
theMultiple Linear Regression method, validating the model
through leave-one-out (LOO) cross-validation analysis.
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